# IDEXX Laboratories (IDXX) Q3 2026 earnings

Results filed 2026-11-02 for the quarter ended 2026-09-30. Source page: https://earnings.opennash.com/companies/idxx/2026-q3/
Press release and documents: https://www.sec.gov/Archives/edgar/data/874716/000110465926120892/0001104659-26-120892-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

IDEXX placed over 1,900 inVue Dx analyzers in the quarter and bought AI clinical assistant CoVet, extending its diagnostics-plus-software push in veterinary practices.

IDEXX's growth this quarter was driven by volume, led by the inVue Dx analyzer, which had over 1,900 placements and brings the installed base to nearly 11,000 instruments. The premium instrument base grew 11% globally, and VetLab consumables use rose with new product launches. IDEXX Cancer Dx became a multi-cancer panel. International regions grew faster than the U.S., and imaging installations were strong, led by ImageVue DR50 Plus.
Management is pairing diagnostics with software, adding the CoVet AI clinical assistant to support veterinary team productivity and diagnostics utilization. Next up is the MultiCue Dx point-of-care analyzer, to be showcased at an investor session at VMX in January. The risks are integrating CoVet, acquisition costs that lowered the full-year operating margin outlook, and rapid assay volumes that are falling.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $1,214 million | an increase of 10% as reported and organic | GAAP |
| Diluted EPS | $4.01 | an increase of 18% as reported and 22% on a comparable basis | GAAP |
| Net income | $317,145 |  | GAAP |
| Gross margin | 62.9% | increased 110 basis points as reported | GAAP |
| Operating income | $402,348 | up 13% as reported | GAAP |
| Operating margin | 33.1% | higher by 100 basis points as reported | GAAP |
| Operating cash flow | $449,717 |  | GAAP |
| Free cash flow | $420,787 |  | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| CAG Diagnostics recurring revenue | $967,351 | up 11% as reported and organic |
| IDEXX VetLab consumables | $443,245 | up 14% reported and 15% organic |
| Reference laboratory diagnostic and consulting services | $399,079 | up 10% reported and organic |
| Rapid assay products | $89,135 | up 1% as reported and organic |
| CAG Diagnostics capital instruments | $51,492 | flat |
| Veterinary software, services and diagnostic imaging systems | $97,125 | up 11% reported and 10% organic |
| Water | $58,836 | up 8% as reported and organic |
| Livestock, Poultry and Dairy | $34,828 | up 3% as reported and organic |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Revenue | 2026 | $4,741 million - $4,767 million |
| Reported operating margin | 2026 | 32.1% - 32.3% |
| EPS | 2026 | $14.96 - $15.16 |
| Capital expenditures | 2026 | ~$160 |

## Key takeaways

1. **inVue Dx placements expand the premium installed base** IDEXX placed over 1,900 inVue Dx analyzers, bringing the installed base to nearly 11,000 instruments. Each placed instrument drives later consumables demand, so placements feed the recurring-revenue model.
2. **CoVet acquisition adds AI to the software strategy** IDEXX acquired CoVet, an AI clinical assistant that supports veterinary team productivity and diagnostics utilization. It links software workflow to testing demand, though integration is a named risk.
3. **Cancer Dx becomes a multi-cancer panel** IDEXX Cancer Dx is now a multi-cancer panel, which IDEXX says helps practices detect disease earlier. It widens the use of reference-lab and in-clinic testing.
4. **Volume, not price alone, drives consumables growth** VetLab consumables grew 14% reported, supported by an 11% larger premium installed base, utilization gains from new launches and net price gains. Rapid assay revenue grew only 1% as price offset lower testing volumes.
5. **International diagnostics outgrows the U.S.** CAG Diagnostics recurring revenue grew 13% reported and 14% organic internationally against 10% in the U.S. IDEXX says both outpaced sector growth.

## Questions

**What was the main product news at IDEXX this quarter?** IDEXX placed over 1,900 inVue Dx analyzers, taking the installed base to nearly 11,000, and expanded IDEXX Cancer Dx into a multi-cancer panel. It also acquired the CoVet AI clinical assistant.
**What is CoVet and why did IDEXX buy it?** CoVet is an AI clinical assistant that supports veterinary team productivity and diagnostics utilization. IDEXX says it creates more value for customers.
**Where is demand strongest?** CAG Diagnostics recurring revenue grew 13% reported internationally versus 10% in the U.S. Growth came from same-store volume, new customers, premium instrument installs and innovation benefits.
**What are the weak spots in the business?** Rapid assay revenue rose only 1% as price gains offset lower testing volumes, and capital instrument revenue was flat. Livestock, Poultry and Dairy grew 3%.
**What is coming next from IDEXX?** IDEXX will present its next point-of-care analyzer, IDEXX MultiCue Dx, at an investor session at VMX on January 18. It also faces CoVet integration, which it cites as a risk.

